Welcome to the Globus Medical's fourth quarter and full year 2024 earnings call. At this time, all lines will be on mute, and ...

In a report released yesterday, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price ...

Medical technologies specialist Globus Medical (NYSE:GMED) reported impressive results for the fourth quarter of 2024 on ...

Globus Medical (GMED) delivered earnings and revenue surprises of 10.53% and 2.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ...

Globus Medical saw fourth quarter net sales grow 6.6% year over year, and full year sales leapt 60.6%, according to financial results posted Feb. 20.

Medical device company Globus Medical (NYSE:GMED) reported Q4 CY2024 results , with sales up 6.6% year on year to $657.3 ...

Globus Medical expects full-year earnings in the range of $3.40 to $3.50 per share, with revenue in the range of $2.66 billion to $2.69 billion. This story was generated by Automated Insights ( http:/ ...

Globus Medical will acquire Nevro in an all-cash transaction. Both company boards of directors have unanimously approved the ...

StockNews.com upgraded shares of Globus Medical (NYSE:GMED – Free Report) from a hold rating to a buy rating in a research ...

Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...